MX365295B - Reduccion del tamaño de particula de un compuesto antimuscarinico. - Google Patents

Reduccion del tamaño de particula de un compuesto antimuscarinico.

Info

Publication number
MX365295B
MX365295B MX2015014904A MX2015014904A MX365295B MX 365295 B MX365295 B MX 365295B MX 2015014904 A MX2015014904 A MX 2015014904A MX 2015014904 A MX2015014904 A MX 2015014904A MX 365295 B MX365295 B MX 365295B
Authority
MX
Mexico
Prior art keywords
particle size
size reduction
drug
antimuscarinic compound
antimuscarinic
Prior art date
Application number
MX2015014904A
Other languages
English (en)
Other versions
MX2015014904A (es
Inventor
Pasquali Irene
Casazza Andrea
Saunders Mark
Losi Elena
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2015014904A publication Critical patent/MX2015014904A/es
Publication of MX365295B publication Critical patent/MX365295B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un proceso para preparar a particulado cristalino micronizado de una sal de glicopirronio. El proceso incluye suspender al fármaco en un antisolvente inmiscible en agua, en el cual el fármaco tiene poca o ninguna solubilidad y micronizar la suspensión. Las partículas de fármaco que se obtienen como resultado son físicamente estables con respecto a la aglomeración y/o agregación durante el almacenamiento.
MX2015014904A 2013-04-26 2014-04-24 Reduccion del tamaño de particula de un compuesto antimuscarinico. MX365295B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13165483 2013-04-26
PCT/EP2014/058295 WO2014173987A1 (en) 2013-04-26 2014-04-24 Particle size reduction of an antimuscarinic compound

Publications (2)

Publication Number Publication Date
MX2015014904A MX2015014904A (es) 2016-03-07
MX365295B true MX365295B (es) 2019-05-29

Family

ID=48190260

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014904A MX365295B (es) 2013-04-26 2014-04-24 Reduccion del tamaño de particula de un compuesto antimuscarinico.

Country Status (28)

Country Link
US (2) US9393202B2 (es)
EP (2) EP3574895B1 (es)
JP (1) JP6449246B2 (es)
KR (1) KR102198354B1 (es)
CN (1) CN105120841B (es)
AR (1) AR096087A1 (es)
AU (1) AU2014259443B2 (es)
BR (1) BR112015024626B1 (es)
CA (1) CA2910314C (es)
DK (2) DK2988728T3 (es)
ES (2) ES2943109T3 (es)
FI (1) FI3574895T3 (es)
HK (1) HK1216302A1 (es)
HR (2) HRP20230337T1 (es)
HU (2) HUE062002T2 (es)
IL (1) IL242209A (es)
MX (1) MX365295B (es)
MY (1) MY169127A (es)
PH (1) PH12015502449A1 (es)
PL (2) PL2988728T3 (es)
PT (2) PT2988728T (es)
RU (1) RU2667636C2 (es)
SG (1) SG11201508760VA (es)
SI (2) SI3574895T1 (es)
TW (1) TWI630926B (es)
UA (1) UA120418C2 (es)
WO (1) WO2014173987A1 (es)
ZA (1) ZA201507916B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
WO2015004243A1 (en) 2013-07-11 2015-01-15 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
CN107106515A (zh) 2014-10-16 2017-08-29 梯瓦优质制药产品研发股份有限公司 可吸入的配制剂
JP6500522B2 (ja) * 2015-03-16 2019-04-17 セイコーエプソン株式会社 回路装置、物理量検出装置、電子機器及び移動体
PT3377109T (pt) 2015-11-16 2020-05-13 Chiesi Farm Spa Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticoide e um betaadrenérgico
PT3620176T (pt) 2015-11-16 2021-09-28 Chiesi Farm Spa Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
JP6323846B2 (ja) * 2016-04-07 2018-05-16 塩野義製薬株式会社 オピオイドを含有する乱用防止製剤
PT109445B (pt) * 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
EP3490533B1 (en) * 2016-07-29 2020-05-27 Inke, S.A. Particle size stabilization process

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
CA2118517C (en) * 1992-06-10 2003-10-14 Gary G. Liversidge Surface modified nsaid nanoparticles
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
KR20050085035A (ko) * 2002-11-18 2005-08-29 이 아이 듀폰 디 네모아 앤드 캄파니 비구형 분쇄 매체를 사용하는 매체 밀링
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0516549D0 (en) 2005-08-12 2005-09-21 Sulaiman Brian Milling system
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2229148B1 (en) * 2007-12-13 2014-03-05 Novartis AG Process for preparing a particulate and crystalline drug substance
KR20100099281A (ko) * 2007-12-13 2010-09-10 노파르티스 아게 유기 화합물
DE102008000482A1 (de) 2008-03-03 2009-09-10 Zf Friedrichshafen Ag Ölgekühltes Reibschaltelement
EP2321023B1 (en) * 2008-07-18 2016-06-15 Prosonix Limited Process for improving crystallinity of fluticasone particles
EP2435024B1 (en) * 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
JP2014504260A (ja) * 2010-10-15 2014-02-20 グラクソ グループ リミテッド 集合ナノ粒子状薬物製剤、その製造及び使用
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound

Also Published As

Publication number Publication date
UA120418C2 (uk) 2019-12-10
ES2943109T3 (es) 2023-06-09
JP2016521274A (ja) 2016-07-21
PT3574895T (pt) 2023-04-28
TW201521790A (zh) 2015-06-16
HRP20191882T1 (hr) 2019-12-27
SI2988728T1 (sl) 2019-11-29
IL242209A (en) 2017-12-31
AU2014259443A1 (en) 2015-11-12
CN105120841A (zh) 2015-12-02
PT2988728T (pt) 2019-11-18
HUE046213T2 (hu) 2020-02-28
MY169127A (en) 2019-02-18
HUE062002T2 (hu) 2023-09-28
DK2988728T3 (da) 2019-11-04
RU2667636C2 (ru) 2018-09-21
CA2910314A1 (en) 2014-10-30
US9393202B2 (en) 2016-07-19
TWI630926B (zh) 2018-08-01
FI3574895T3 (fi) 2023-05-25
AU2014259443B2 (en) 2019-01-03
PL3574895T3 (pl) 2023-06-19
KR20160002733A (ko) 2016-01-08
US9889094B2 (en) 2018-02-13
DK3574895T3 (da) 2023-05-01
EP2988728A1 (en) 2016-03-02
EP2988728B1 (en) 2019-08-21
WO2014173987A1 (en) 2014-10-30
PH12015502449B1 (en) 2016-02-22
ES2754255T3 (es) 2020-04-16
HRP20230337T1 (hr) 2023-06-09
US20140322142A1 (en) 2014-10-30
CN105120841B (zh) 2019-04-30
BR112015024626A2 (pt) 2017-07-18
AR096087A1 (es) 2015-12-02
ZA201507916B (en) 2017-05-31
JP6449246B2 (ja) 2019-01-09
PL2988728T3 (pl) 2020-02-28
KR102198354B1 (ko) 2021-01-06
PH12015502449A1 (en) 2016-02-22
HK1216302A1 (zh) 2016-11-04
BR112015024626B1 (pt) 2022-11-01
MX2015014904A (es) 2016-03-07
RU2015145521A (ru) 2017-05-16
SG11201508760VA (en) 2015-11-27
SI3574895T1 (sl) 2023-05-31
US20160279066A1 (en) 2016-09-29
EP3574895B1 (en) 2023-03-22
EP3574895A1 (en) 2019-12-04
CA2910314C (en) 2022-03-01

Similar Documents

Publication Publication Date Title
PH12015502449A1 (en) Particle size reduction of an antimuscarinic compound
HK1211579A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl- cyano-methyl)-amides inhibitors of athepsin 2--[221]-3-(--)-
IL240963A0 (en) Respirable agglomerates of airborne carrier particles and miniaturized drugs
HRP20221047T1 (hr) Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
WO2013132457A3 (en) Nanocrystalline solid dispersion compositions and process of preparation thereof
EA201590161A1 (ru) Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
PH12016500814A1 (en) Heteroaryl butanoic acid derivatives
MX2018005520A (es) Metodos para preparacion de acido obeticolico y derivados de los mismos.
PH12015501877A1 (en) Suspension for oral administration comprising amorphous tolvaptan
LT2612851T (lt) Perindoprilio l-arginino druskos gamybos būdas
HK1220444A1 (zh) 拉喹莫德鈉晶體和用於製造它們的改進方法
GB201813024D0 (en) System and methods for aggregation of cloud storage
HUP1300647A2 (hu) Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
WO2015138928A3 (en) Mixed mode ligands
HK1187061A1 (en) Delta crystalline form of the arginine salt of perindopril, a process for its preparation, and pharmaceutical compositions containing it
MX2015016958A (es) Sintesis de dicarbamatos de isohexida y derivados de estos.
MX2018013764A (es) Cristal de derivado de quinolina.
HK1205449A1 (en) Package for solid preparation including 5-hydroxy-1h-imidazole-4- carboxamide or salt or hydrate thereof 5--1h--4-
PT3066076T (pt) Processo de preparação de metilfenidato de metilo e dos respetivos sais farmacêuticos
MX2018008824A (es) Preparacion de particulas micronizadas de un compuesto antimuscarinico por cavitacion hidrodinamica.
PH12016500261A1 (en) Nanoparticles and nanoparticle composition, and method for producing nanoparticles and nanoparticle composition
TH163807B (th) การลดขนาดอนุภาคของสารประกอบต้านมัสคารีน
IN2014MU00328A (es)
GR1007770B (el) Φαρμακευτικο σκευασμα περιεχον ρεπαγλινιδη και μεθοδος για την παρασκευη αυτου
RU2014144841A (ru) Способ эндотелиопротекции наноструктурированным L-аргинином

Legal Events

Date Code Title Description
FG Grant or registration